Advanced Search

Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2014 June;26(2) > Minerva Biotecnologica 2014 June;26(2):103-13



A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Frequency: Quarterly

ISSN 1120-4826

Online ISSN 1827-160X


Minerva Biotecnologica 2014 June;26(2):103-13

MicroRNAs: from basic research to therapeutic applications 


MicroRNA “Theranostics”: technology transfer and clinical trials

Gambari R.

Section of Biochemistry and Molecular Biology, Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy

MicroRNAs are very promising targets for diagnosis and prognosis of human pathologies. In addition, therapeutic molecules mimicking miRNA biological activity, or molecules inhibiting miRNA (antagomiRNAs) represent important tools for novel strategies to control and modify gene expression in eukaryotic systems, in vitro and in vivo. Therefore, miRNAs are key target in Teranostics. Among the molecules studied for “miRNA Therapeutics”, they are designed to mimic (miRNA replacement therapy) or to interfere with (antagomiRNA-based therapy) miRNA activity. Patents, patents applications and ongoing clinical trials based on miRNA targeting demonstrate the interest on this field of investigation for technology transfer.

language: English


top of page